Document Type: Research Articles
Department of Chemical Pathology, Medical Research Institute, Faculty of Medicine, Alexandria University, Egypt.
Department of Biochemistry, Faculty of Medicine, Alexandria University, Egypt.
Department of Urology, Faculty of Medicine, Alexandria University, Egypt.
Department of Microbiology, Faculty of Medicine, Alexandria University, Egypt.
Abdominal imaging leads to the detection of a large number of renal tumors without the ability to distinguish the
type of tumor detected. It is necessary to find a precise way to know the type of tumor to determine the appropriate
treatment. The use of urine samples for detecting new biomarkers especially proteins has a great potential. In this work
we assessed the proteomic profiling difference in a cohort of Egyptian population with renal neoplasms. Methods:
This cohort study was conducted on 85 subjects. They were classified as 40 RCC, 15 benign kidney patients, and 30
healthy controls. Morning urine samples were used for peptidome separation using magnetic beads. Matrix assisted laser
desorption ionization time of flight mass spectrometry (MALDI-TOF MS) was applied Using FlexControlTM software.
Results: Benign tumors were differentiated from controls by 5 integrated peaks, 12 significant and 2 integrated significant
peaks, 17:3,418.8 and 25:4,173.41. While RCC were differentiated from benign by 5 integrated, 28 significant and one
integrated significant peak. The RCC group was discriminated from the controls by 5 peaks which were integrated from
which 1 was integrated and significant (with mass to charge ratio of 12:3,408.97). The three groups showed protein
profiles ranging from 1 to 10 kDa. The external validation was performed for the RCC group versus the control reveled
sensitivity of 88.7% and specificity of 73.2% by genetic algorithm. Conclusion: Proteomic approach can be used as a
sensitive urinary marker differentiating renal masses in an early diagnostic approach.